Michael Rice is the CEO of BioLife Solutions, a leading supplier of class-defining cell and gene therapy bioproduction tools and services.
Rice joined the company in 2006 as president, CEO and director, and he served as chairman of the board from 2007 to 2013. In his last five years with the company, Rice has driven annual revenue growth to greater than 30 percent. During his tenure, BioLife has twice been named one of Seattle Business Magazine’s 100 Best Companies to Work For.
Prior to BioLife, Rice spent two years as the senior business development manager of medical and wireless products for AMI Semiconductor Inc. His career includes 30 years of experience in leadership and entrepreneurial roles in the medical and high-tech industries, including a four-year stint at Cardiac Science where he worked as the director of business development and marketing. From 1998 to 2000, Rice served as VP of sales and marketing for TEGRIS Corporation, a privately-held network services provider.
Early in his career, Rice held a series of marketing and sales management roles at Physio Control Corporation before it was acquired by Medtronic. He currently serves on the board of Sexton Biotechnologies, and he was formerly a board member for Savsu Technologies from 2014 to 2019.
Rice earned his B.S. in business administration from City University of Seattle.
What is Michael Rice's net worth?
The estimated net worth of Michael Rice is at least $9.51 million as of October 30th, 2023. Mr. Rice owns 347,085 shares of BioLife Solutions stock worth more than $9,506,658 as of December 21st. This net worth estimate does not reflect any other investments that Mr. Rice may own. Learn More about Michael Rice's net worth.
How do I contact Michael Rice?
Has Michael Rice been buying or selling shares of BioLife Solutions?
Michael Rice has not been actively trading shares of BioLife Solutions during the last ninety days. Most recently, Michael Rice sold 72,603 shares of the business's stock in a transaction on Monday, October 30th. The shares were sold at an average price of $9.13, for a transaction totalling $662,865.39. Following the completion of the sale, the chief executive officer now directly owns 347,085 shares of the company's stock, valued at $3,168,886.05. Learn More on Michael Rice's trading history.
Who are BioLife Solutions' active insiders?
Are insiders buying or selling shares of BioLife Solutions?
In the last twelve months, insiders at the medical equipment provider sold shares 75 times. They sold a total of 143,570 shares worth more than $2,926,356.42. The most recent insider tranaction occured on December, 16th when EVP Aby J Mathew sold 7,604 shares worth more than $207,817.32. Insiders at BioLife Solutions own 2.2% of the company.
Learn More about insider trades at BioLife Solutions. Information on this page was last updated on 12/16/2024.